Investor Relations

Latest Presentation

Corporate Presentation

Latest Event

Annual Meeting of Shareholders

Latest Financial Results

Q2 2024

Quarter Ended Feb 29, 2024

Latest Annual Filing

For Fiscal Year Ending Aug 31, 2023

Company Overview

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 43 patents granted and many patents pending worldwide.

Stock Snapshot

IR Contacts

Headquarters

Canadian Operations

#100-740 McCurdy Road
Kelowna, BC V1X 2P7

US Operations

105 Peach State Court
Suite A
Tyrone, GA 30290

Investor Relations

IR contact
T: 250-765-6424 ext. 202
IR@lexariabioscience.com

Transfer Agent

Computershare Investor Services Inc.
T: 800-564-6253
https://www.computershare.com

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Back to the top